A Study of LY4355756 in Healthy Participants

Part of paid clinical trials in Dallas, Texas.

Sponsor
Eli Lilly and Company
Study ID
NCT07765498
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4355756 — DRUG
    Administered orally as capsule
  • LY4355756 — DRUG
    Administered orally as tablet
  • Midazolam — DRUG
    Administered orally as liquid

Study Details

The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants. There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.

Key Dates

First listed
Aug 14, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
123 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4355756 Part A
    Single-ascending dose (SAD) of LY4355756 administered orally
  • Experimental: LY4355756 Part B
    Multiple-ascending doses (MAD) of LY4355756 administered orally
  • Experimental: LY4355756 Part C
    Single dose of LY4355756 administered orally in each of three study periods
  • Experimental: LY4355756 + Midazolam Part D
    LY4355756 and midazolam co-administered orally
  • Experimental: Midazolam Part D
    Midazolam administered orally

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to the Safety Follow up Visit (6 months) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDallasTexas75247
469-513-6669
Gene Voskuhl (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dallas, TX

By research site
Fortrea Clinical Research Unit· Dallas, TX

Related Studies